
On October 13th, the Trump administration’s new rule banning federal funds from being used to cover care for trans youth through Medicaid and CHIP went into effect. Both programs, which are funded jointly by the federal government and individual states, provide health insurance to low-income Americans, and under them, states decide what care they will and will not cover. As the rule stipulates, states wishing to continue covering gender-affirming care for minors must use their own funds to take on “the full cost of sex-rejecting procedures.”
Last month, Transitics reported that Arizona and Virginia had ended coverage of care for trans youth in response to the rule, and a week later, Transitics reported that Colorado and Michigan had joined that list as well. The latter article also identified a dozen states—California, Delaware, Hawaii, Illinois, Maine, Maryland, Massachusetts, New Mexico, New York, Oregon, Vermont, and Washington—that had already announced (or, in Delaware’s case, quietly decided) that they would be continuing coverage using their own funds.
But since then, there’s been a number of new updates, some good and some bad. And we’ll start with the bad. As of today, Transitics can confirm that two more blue states have cut coverage of gender-affirming care for minors: Connecticut and Rhode Island.
Firstly, there’s Connecticut. On October 2nd, the Connecticut Department of Social Services (DSS) published a bulletin to its website informing providers that, because of the new rule, they would have to include a diagnosis code when billing “drug products commonly used for gender affirmation.” After this was posted, Transitics contacted the Connecticut Department of Social Services for clarification and was told that a decision had not yet been made on the issue.
Now, it appears that a decision has been made. On October 28th, the DSS notified providers that, among other things, it had updated its “Gender Affirmation Surgery” policy effective November 1st. Previously, the policy included a section titled “adolescents,” which stated that “gender affirming surgery for individuals under 18 years of age will be reviewed on a case-by-case basis.” As part of the update, however, this section was removed, and every surgery now specifically indicates that it’ll only be covered “when the individual is 18 years of age or older.” This also applies to laser hair removal, which isn’t a surgery.
The policy also includes a history at the end, and this lists the relatively small changes that the Department had initially planned on making to it as part of an annual review. But after these were approved at the ‘Medical Reviewer meeting’ on August 26th, the DSS administration—which doesn’t normally dictate the contents of its policies—apparently stepped in to make one final change:
“Additional changes made by DSS on September 14, 2026, limiting coverage to individuals 18 years of age or older, changes made throughout policy to reflect this.”
While the state doesn’t mention the Trump rule by name, the timing of this decision is no accident. Moreover, given the fact that the state doesn’t have a policy for non-surgical gender-affirming care and that—as previously mentioned—the age restriction also applies to laser hair removal, it’s almost certain that the acquiescence applies to hormone therapy and puberty blockers as well. Worse, as is commonly the case, the state does not appear to have made any effort to inform patients or their families about the change in policy.
Transitics has made several attempts over the past few days to contact the DSS about the changes but has not received an answer.
And Connecticut isn’t alone. To the east, Rhode Island somehow found what might be the worst way a state has handled this thus far. In fact, unlike the other states that have cut coverage for trans youth, the Rhode Island Executive Office of Health and Human Services (EOHHS) has not addressed or even mentioned the rule in any way. Instead, we have to look to the Managed Care Organizations (MCOs) it contracts to administer its program, and there, we very quickly find our answer.
Indeed, on November 3rd, the Neighborhood Health Plan of Rhode Island (NHPRI) published its updated ‘Gender Affirmation’ policy, which it says was last reviewed on October 14th—2 months earlier than normally scheduled and one day after the rule’s effective date. There, it made the following change:
“Pharmacological therapy & hormonal therapy, for members less than 18 years of age for a diagnosis of Gender Incongruence (F64.0…) is NOT covered in the Medicaid and Medicare Lines of Business.”
Furthermore, “pharmacological and hormonal therapy for gender dysphoria for members less than 18 years of age” was added to its list of exclusions. As shown by archived versions of the policy, only surgery for minors was previously excluded, while other forms of gender-affirming care for minors were explicitly listed as covered services. It does not mention a ‘tapering period.’
And even if Rhode Island’s capitulation is limited to NHPRI—and it almost certainly isn’t—it’s still highly impactful. According to a report published by EOHHS in 2023, NHPRI provides coverage to around 115,000 children and families, a total that accounts for 61.4% of all children and families enrolled in Medicaid in the state; the other MCOs, UnitedHealthcare and Tufts Health Plan, do not publish gender-affirming care policies specific to Rhode Island.
As was the case with Connecticut, Transitics has reached out to the EOHHS regarding these changes and has not received a response.
That aside, there’s also good news. On November 2nd, Michigan announced that it would not be cutting coverage for trans youth after all, and that instead, “the State of Michigan Medicaid Program will continue to cover these treatments according to Michigan Medicaid fee-for-service pharmacy rules and restrictions using state general funds.” Meanwhile, on October 15th, it was also reported—and independently confirmed by Transitics one day later—that Pennsylvania would be using state funds to protect trans kids’ care access as well.
And that’s not all, as Transitics has also confirmed that two more purple states will be using state funds to protect care for trans youth: Nevada and Wisconsin.
In Nevada, the state announced on October 26th that, in response to the rule, it will “continue to pay for [gender-affirming medications for ‘pediatric patients’] using state funds.” It’s worth noting that the state’s governor is currently a Republican, Joe Lombardo. Interestingly, Lombardo has made several efforts to pass anti-trans policies, including a sports ban, and although Nevada law does explicitly mandate that its Medicaid program cover gender-affirming care for all ages, it should be mentioned that Colorado cut its coverage despite having a similar law on the books.
Why Lombardo’s administration made the decision to cover this care, as well as why they did so publicly, is unknown. Regardless, Lombardo lost his bid for reelection last week and will be replaced by Democrat Aaron Ford in January. Ford is currently the state’s attorney general and has joined the lawsuit challenging the rule, meaning he likely won’t reverse the decision to use state funds.
Wisconsin, meanwhile, has not gone public about its decision to continue care, but state Department of Health Services (DHS) Deputy Director of Clinical Policy Susan Seibert told Transitics in a phone call that the DHS is “continuing to cover those services [gender-affirming care for minors] with DHS-only funds.” Although Wisconsin’s governor, Tony Evers, is an outspoken trans ally, the state’s legislature has been under Republican control since 2011.
Evers will be succeeded by fellow Democrat David Crowley—who is also an outspoken trans ally—in January. Unlike Evers, Crowley will govern alongside a Democratic majority in the legislature.
Lastly, there are two states whose announcements were, oddly enough, more informative and perplexing than they were anger-inducing. The first of these is Montana. On October 7th, the Montana Department of Public Health and Human Services (DPHHS) quietly posted a notice to its website stating that it would be cutting coverage of gender-affirming care for minors. Like Colorado, the ‘tapering period’ only applies to hormone therapy, not puberty blockers.
Nevertheless, in this same document, the DPHHS also did something else: confirm that gender-affirming care for adults—including surgery—is actually covered by Montana’s Medicaid program. It’s worth noting that before this statement, whether Montana Medicaid covered any gender-affirming care at all remained an open question, and the last time it had acknowledged the topic was before former Democratic governor Steve Bullock left office nearly 6 years ago. And as Transitics reported this past January, the state had also indicated in 2021 that gender-affirming surgery was no longer covered, meaning that this stance is now confirmed to have been reversed as well.
But perhaps the most interesting is North Dakota. Since 2022, North Dakota has been one of the few red states to cover gender-affirming care under its Medicaid program, and unlike Montana, the state has been rather public about this. Indeed, for the past three years, North Dakota’s Department of Health and Human Services (HHS) has outlined its coverage in a policy titled “Gender Affirming Care and Services.”
At the same time, North Dakota passed a law in 2023 that bans gender-affirming care for minors in the state. Similarly to other states, this was understood to mean that the state wouldn’t fund this care either. However, this past April, Transitics identified a loophole that, at least in theory, meant care for trans youth was actually still covered, as under North Dakota’s Medicaid program, providers that are in another state—like Minnesota—but within 50 miles of the state’s borders are considered to be ‘in-state.’ This hypothesis was also supported by the fact that the policy continued to list puberty blockers as a covered service.
On October 15th, the HHS all but confirmed this had been the case, updating the policy to announce that gender-affirming care for youth would no longer be covered as a result of the rule. Although it only mentions a 6-month ‘tapering period’ for ‘hormone therapy,’ given that the policy previously listed puberty blockers under ‘hormone therapy,’ this can be understood to apply to both.
At this point, if you’re a trans adult, you may be asking yourself, “Why should this issue matter to me?” After all, trans kids who receive gender-affirming care are just a fraction of the trans population. Thus, as long as care for adults isn’t affected, you may not feel that these cuts are worth fighting against.
But we must remember that with these capitulations, the issue is much broader than just trans youth. At the end of the day, the Trump administration implemented the rule in order to limit trans kids’ access to the care that they need. And if states step in to ensure this care remains covered, the rule won’t accomplish its intended purpose. Even if just one of those states refuses, though, they’ve already won.
Furthermore, much in the same way that this rule was implemented without congressional approval, a rule banning federal funds from going towards care for adults can be enacted just as easily. And right now, Arizona, Colorado, Connecticut, Rhode Island, and Virginia are showing the federal government that not every state is willing to step in to stop trans people—regardless of age—from losing their healthcare.
Perhaps, when it comes to adults, they will.
But if they’re not fighting now, how can we know they’ll fight later?

